Skip to main content
Fig. 2 | Molecular Cancer

Fig. 2

From: Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer

Fig. 2

Distributions of PIK3CA, AKT1, and ESR1 mutations according to each TL in ER-positive breast cancer. The bar graphs show PIK3CA mutations (gray monochrome), ESR1 mutations (gray horizontal stripes), and AKT1 mutation (black monochrome) from the left in each category. a The subgroup in the primary and each TL (the 1st/2nd line, the 3rd/4th line, the 5thā€“7th line, and the 8th line or more line) were omitted. The subgroup in each endocrine therapy line; b, and in each chemotherapy line; c, (the 1st line, the 2nd/3rd line, the 4th/5th line, and the 6th line or more line) were omitted. Abbreviations: ER, estrogen receptor; P, PIK3CA mutations; E, ESR1 mutations; A, AKT1 mutation

Back to article page